Form 4: ImmunityBio CEO Richard Adcock Reports Stock Transactions
SEC Form 4
CEO Richard Adcock reports the vesting of restricted stock units and subsequent stock transactions.
Summary
- On December 31, 2024, Richard Adcock, CEO and President of ImmunityBio, Inc., reported transactions involving ImmunityBio's common stock and restricted stock units (RSUs).
- Adcock acquired 34,483 shares of common stock through the vesting of restricted stock units.
- Simultaneously, Adcock disposed of 17,475 shares of common stock at a price of $2.56 per share to cover tax obligations.
- Following these transactions, Adcock directly owns 260,146 shares of ImmunityBio common stock and 86,214 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. This provides transparency to the market.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 09/09/2021 | 5% of the RSUs vested |
| 12/31/2022 | 5% of the RSUs vested |
| 12/31/2023 | 20% of the RSUs vested |
| 12/31/2024 | Date of stock transactions and vesting of 20% of RSUs |
| 12/31/2025 | 20% of the RSUs will vest |
| 12/31/2026 | Remaining RSUs will vest |
| 01/03/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.